Functionally gene-linked polymorphic regions and genetically controlled neurotransmitters metabolism

European Neuropsychopharmacology

Volumn 11, Issue 6, 2001, Pages 431-439

  Catalano, M ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Mood disorders; Neurotransmitters; Panic disorder; Pharmacogenetics

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; CLOZAPINE; CYTOCHROME P450; DOPAMINE; DOPAMINE 4 RECEPTOR; FLUVOXAMINE; MOCLOBEMIDE; NEUROLEPTIC AGENT; NORADRENALIN; PAROXETINE; PINDOLOL; POSTSYNAPTIC RECEPTOR; PSYCHOTROPIC AGENT; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR;

DEPRESSION; ENZYME ACTIVITY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MENTAL DISEASE; MONOAMINE METABOLISM; NEUROTRANSMISSION; NONHUMAN; PANIC; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; PSYCHOPHARMACOLOGY; REVIEW;

EID: 0034747816     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(01)00120-1     Document Type: Article

References (77)

1. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients
2. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype
3. Influence of a functional polymorphism within the promoter of the serotonin transporter gene on the effects of total sleep deprivation in bipolar depression
4. Association between tridimensional personality questionnaire (TPQ) traits and three functional polymorphisms: dopamine receptor D4 (DRD4), serotonin transporter promoter region (5-HTTLPR) and catechol-O-methyltransferase (COMT)
5. An interaction between the catechol-O-methyltransferase and serotonin transporter promoter region polymorphisms contributes to tridimensional personality questionnaire persistence scores in normal subjects
6. Obsessive compulsive disorder, response to serotonin reuptake inhibitors and the serotonin transporter gene
7. Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses
8. Serotonin transporter polymorphisms and response to SSRIs in different psychiatric disorders: a mirror of etiopathogenetic differences?
9. Orphan receptors, novel neuropeptides and reverse pharmaceutical research
10. Post-transcriptional gene regulatory mechanisms in eukaryotes: an overview
11. Linkage disequilibrium on the COMT gene in French schizophrenics and controls
12. Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder
13. Pilot study of the cytochrome P450-2D6 genotype in a psychiatric state hospital
14. Ethnicity and antipsychotic response
15. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees
16. Ultradian rapid cycling in prepubertal and early adolescent bipolarity is not in transmission disequilibrium with val/met COMT alleles
17. Association between the serotonin transporter promoter polymorphism and personality traits in a primarily female population sample
18. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder
19. Chromosomal mapping of the human catechol-O-methyltransferase gene to 22q11.1-q11.2
20. Role of the serotonin transporter gene in temperament and character
21. Allelic variation of human serotonin transporter gene expression
22. COMT and DRD3 polymorphisms, environmental exposures, and personality traits related to common mental disorders
23. Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia
24. Initiation and adaptation: a paradigm for understanding psychotropic drug action
25. Initial sequencing and analysis of the human genome
26. Ethical considerations in clinical pharmacogenomics research
27. Pharmacogenetics and cancer chemotherapy
28. Pharmacogenetics in biological perspective
29. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia
30. Family-based association studies support a sexually dimorphic effect of COMT and MAOA on genetic susceptibility to obsessive-compulsive disorder
31. Neuroleptic malignant syndrome and hydroxylase gene mutations: no association with CYP2D6A or CYP2D6B
32. Serotonin transporter gene polymorphism and antidepressant response
33. Family-based association studies of bipolar disorder with candidate genes involved in dopamine neurotransmission: DBH, DAT1, COMT, DRD2, DRD3 and DRD5
34. Low activity allele of catechol-O-methyltransferase gene associated with rapid cycling bipolar disorder
35. Differential regulation of rat 5-HT2A and 5-HT2C receptors after chronic treatment with clozapine, chlorpromazine and three putative atypical antipsychotics drugs
36. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential applications to neuropsychiatric disorders
37. Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome
38. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region
39. Genetically driven variation in serotonin uptake: is there a link to affective spectrum, neurodevelopmental, and neurodegenerative disorders?
40. Family-based linkage disequilibrium mapping using S.N.P. marker haplotypes: application to a potential locus for schizophrenia at chromosome 22q11
41. Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine
42. Ethnic differences in catechol-O-methyltransferase pharmacogenetics: frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or Southwest Asian individuals
43. An overview of the mechanism of action of clozapine
44. Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine
45. The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients
46. Pharmacological treatment of obsessive-compulsive disorder
47. Preliminary evidence of an association between bipolar disorder in females and the catechol-O-methyltransferase gene
48. Transmission-ratio distortion of X chromosomes among male offspring of females with skewed X-inactivation
49. Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist?
50. Association and linkage of anxiety-related traits with a functional polymorphism of the serotonin transporter gene regulatory region in Israeli sibling pairs
51. Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles
52. Bipolar spectrum disorders in patients diagnosed with velo-cardio-facial syndrome: does a hemizygous deletion of chromosome 22q11 result in bipolar affective disorder?
53. The medical utility of genomics data in neuropsychiatry: mutational genetics versus association genetics
54. A SNP shot: pharmacogenetics and the future of drug therapy
55. Artificial neural networks: a study in clinical psychopharmacology
56. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression
57. Psycotic illness in patients diagnosed with velo-cardio-facial syndrome and their relatives
58. Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine
59. Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene
60. Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients
61. Late onset psycosis in velo-cardio-facial syndrome
62. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine
63. Ethnicity and pharmacogenetics
64. Panic and phobic anxiety: defining phenotypes for genetic studies
65. Recent progress in psychiatric genetics-some hope but no hype
66. Brain elimination half-life of fluvoxamine measured by 19F magnetic resonance spectroscopy
67. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder
68. Over the mainstream: diagnostic requirements for biological psychiatric research
69. Black and white patients response to antidepressant treatment for major depression
70. The sequence of the human genome
71. Lack of evidence for association between the COMT locus and schizophrenia
72. Serotonin transporter knock-out mice show a spontaneous behavioral phenotype of increased 'anxiety' and stress responses
73. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of serotonin transporter gene
74. Expression and characterization of a dopamine D4R variant associated with delusional disorder